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Abstract To describe the key diagnostic features of
pediatric Guillain–Barre´ syndrome (GBS) and validate the
Brighton criteria. Retrospective cohort study of all children
(\18 years) diagnosed with GBS between 1987 and 2013
at Sophia Children’s Hospital, Erasmus MC, Rotterdam.
Clinical information was collected and the sensitivity of the
Brighton criteria was calculated. 67 children (35 boys)
were included, with a median age of 5.0 years [interquar-
tile range (IQR) 3.0–10.0 years]. Bilateral limb weakness
was present at hospital admission in 93% of children, and
at nadir in all patients. Children presented with tetraparesis
in 70% or with paraparesis in 23%. Reduced reflexes in
paretic limbs were observed at hospital admission in 82%
and during follow-up in all children. The progressive phase
lasted median 6 days (IQR 3–8 days) and less than
4 weeks in all children. A monophasic disease course was
seen in 97%, including 5 children with a treatment-related
fluctuation. Two children had a later relapse at 9 weeks and
19 weeks after onset. 77% of the children showed an ele-
vated protein level in CSF. Nerve conduction studies
showed evidence for a poly(radiculo)neuropathy in 91% of
the children. 46 children had a complete data set, the
sensitivity of the Brighton criteria level 1 was 72% (95%
CI 57–84) and 96% (95% CI 85–99) for level 2 and 98%
(95% CI 88–100) for level 3. The majority of the pediatric
GBS patients presented in this cohort fulfilled the current
diagnostic criteria.
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Introduction
The Guillain–Barre´ syndrome (GBS) is a clinical diagno-
sis, supported by the results of the cerebrospinal fluid
(CSF) and nerve conduction studies (NCS) [1]. Recogni-
tion of GBS is important to start treatment and monitoring
as soon as possible. Accurate diagnostic criteria for GBS
are also required to determine background incidence rates
and to conduct vaccine safety studies. For this purpose,
criteria for GBS were developed in 1978 by the National
Institute of Neurological and Communicative Disorders
and Stroke (NINDS) and updated in 1990 [2]. In response
to the H1N1 vaccination campaign in 2009 and its possible
relation with GBS, new case definitions for GBS were
developed by the Brighton Collaboration, an international
collaboration sponsored by the World Health Organization
to improve vaccine safety monitoring [3]. Previous studies
have validated the Brighton criteria in cohorts of adult
patients with GBS from South Korea and The Netherlands
[4, 5]. The Brighton criteria also require validation for GBS
in children, which may differ considerably from GBS in
adults [6].
In 2011 the Brighton criteria were validated in children
from India, but the clinical presentation of GBS in India is
not the same as in a Western country. Therefore, in this
study, we describe in detail the clinical presentation and
course of GBS in children, focussing on the key diagnostic
characteristics, and validate the Brighton criteria for pedi-
atric GBS.
Patients and methods
Medical files and discharge letters from all children
(\18 years) diagnosed with GBS at Sophia Children’s
Hospital, Erasmus MC, Rotterdam, The Netherlands,
between 1987 and 2013, were reviewed retrospectively.
Part of this cohort has been described previously for dif-
ferent purposes [6]. The revised version of the NINDS
diagnostic criteria from 1990 [2] was used as guideline for
the diagnosis. Patients with Miller Fisher syndrome, acute
onset chronic inflammatory demyelinating polyneuropathy
(CIDP) or other neurological diseases or comorbidity
influencing the GBS diagnosis were excluded. Data were
collected regarding age, sex, preceding events, onset of
weakness, neurological signs and symptoms at hospital
entry, clinical course, and results from CSF examination
and NCS. Severity of the disease at nadir was defined by
the highest GBS disability score (Table 1) [7].
Symmetrical weakness was defined as the absence of
difference in muscle weakness in major limb muscle
groups on the left versus the right side.
A clinical fluctuation was previously defined as an
improvement or stabilization longer than 1 week followed
by secondary deterioration of at least one grade in the GBS
disability score [8, 9]. A treatment-related fluctuation
(TRF) was defined previously as a clinical fluctuation due
to the transient effect of the treatment that usually occurs
within 8 weeks after start of treatment [8].
CSF was examined for protein level and for cell count.
All results of the NCS were reviewed by a clinical neu-
rophysiologist (JD) and were considered supportive of the
clinical diagnosis if consistent with the criteria for acute
inflammatory demyelinating polyneuropathy (AIDP), acute
motor axonal neuropathy (AMAN), acute motor axonal
sensory neuropathy (AMSAN) or inexcitable nerves [10].
An equivocal electrophysiological result not meeting the
Table 1 Neurological deficits at admission and nadir in 67 children
with GBS
Demography Presentation
Male/female ratio 35/32
Age at admission (years)a 5 (IQR 3–10, range 0–16)
Antecedent events
Diarrhea 40% (25/64)
Upper respiratory tract infection 41% (27/66)
Vaccination 8% (5/67)
Admission Nadir
Neurological signs and symptoms
Cranial nerve deficits 53% (32/61) 60% (39/65)
Sensory deficits 30% (12/40) 40% (19/48)
Pain 73% (47/64) 84% (54/64)
Bilateral weakness 93% (55/59) 100% (65/65)
Tetraparesis 70% (40/57) 88% (57/65)
Paraparesis (of the legs) 23% (13/57) 11% (7/65)
Decreased reflexes in weak limbs 82% (45/55) 100% (62/62)
Autonomic dysfunction 12% (8/67) 53% (35/66)
Blood pressure fluctuations 6% (4/66) 35% (23/65)
Cardiac dysrhythmia 3% (2/67) 15% (10/66)
Bladder dysfunction 6% (4/65) 25% (16/64)
GBS disability scoreb
2 35% (23/66) 8% (5/67)
3 26% (17/66) 16% (11/67)
4 36% (24/66) 51% (34/67)
5 3% (2/66) 24% (16/67)
6 0% (0/66) 2% (1/67)
2 able to walk 10 m unaided, unable to run, 3 able to walk 10 m with
aid, 4 Bedridden or chairbound, 5 requiring assisted ventilation, 6
deceased
a Median (interquartal range and full range)
b GBS disability score
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criteria for one of these subtypes, but still consistent with
the diagnosis GBS, was recorded separately [5].
The Brighton criteria consist of four levels of diagnostic
certainty. Level one has the highest diagnostic certainty;
these patients fulfil all diagnostic criteria. Level 4 has the
lowest diagnostic certainty, these patients do not fulfil the
criteria of level 3 but all other diagnoses are excluded. The
diagnostic criteria needed to fulfil each level are shown in
online only Table 1. All patients in this study were clas-
sified according to the Brighton criteria. This was done for
the entire cohort and also in a subgroup of patients in
whom all clinical information regarding the six key diag-
nostic features were present. Sensitivity of the Brighton
criteria was calculated for the levels 1, 2 and 3.
The study was approved by the medical ethical review
committee of the Erasmus MC.
Statistical analysis
Continuous data were presented as means and standard
deviations if normally distributed, and as medians and
interquartile ranges (IQR) when not normally distributed.
Categorical data were presented as proportions. Shapiro–
Wilk test was used to define if the data were normally
distributed. Continuous data were compared with t test if
normally distributed and with Mann–Whitney U test if not
normally distributed. Proportions were compared using the
Chi-square or Fisher exact test. Correlations between cat-
egorical data were tested using the Spearman correlation.
SPSS Statistics 20.0 was used for the statistical analyses. A
two-sided p value\0.05 was considered to be statistically
significant.
Results
The clinical features of 67 children diagnosed with GBS
included in the study are shown in Table 1. The key
diagnostic characteristics important for the Brighton cri-
teria are described in more detail.
Muscle weakness
At admission all children presented with symmetrical limb
weakness, except four cases (6%). These four children
without weakness initially presented with different symp-
toms or signs, including neck stiffness, facial weakness and
limb muscle pain. In the following days, all developed a
symmetrical tetraparesis and were diagnosed with GBS. At
hospital admission, 13 (23%) children presented with
weakness restricted to the legs. During the course of the
disease, six of them developed additional weakness of the
arms. The remaining seven (11%) children showed
persistent paraparesis of the legs during follow-up,
although three of them developed reduced reflexes of the
arms.
Reflexes
At admission, most children had decreased reflexes in weak
limbs (Table 1). One child initially had hyperreflexia in
weak limbs with plantar reflexes and a normal MRI of
cerebrum and myelum, excluding transverse myelitis. This
patient developed hyporeflexia during the course of the
disease.
Course of the disease
All children reached nadir within 28 days of onset of
weakness and 43 (66%) children already within 1 week. 65
children (97%) had a monophasic disease course. Five
(8%) children had a clinical fluctuation within 8 weeks of
onset of weakness, which were interpreted as TRF but
considered compatible with a monophasic disease course.
Two of these children received a second course of IVIg
because of the severity of the deterioration. Two (3%)
children had a clinical fluctuation more than 8 weeks after
onset of weakness. One child deteriorated at day 59 but the
weakness was milder than the first episode. The other child
had a clinical fluctuation at day 137 during a Shigella
gastro-enteritis. Both children recovered spontaneously and
no further fluctuations occurred.
One child had a relapsing GBS with two recurrences at 3
and 23 years after the first episode. She was treated with a
course of IVIg after each episode with a good clinical
response and was stable without residual symptoms
between these episodes. One patient died during the course
of the disease due to severe autonomic dysfunction.
Treatment
In this cohort, only 6 children (9%) did not receive specific
treatment for GBS. The majority of the children received
either IVIg alone (N = 49, 77%) or plasma exchange alone
(N = 1, 2%) or a combination of IVIg and prednisone/
methylprednisolone (N = 8, 13%). This last category of
patients participated in the randomized controlled trial
comparing IVIg and methylprednisolone (MP) versus IVIg
and placebo (Koningsveld et al. 2004) [11]. Some patients
received IVIg and MP shortly after finalizing the trial
considering that this combination was related with better
outcome after adjustment for age and GBS disability score.
One of these eight children had increased intracranial
pressure during the acute phase of GBS for which he
received IV steroids.
J Neurol
123
CSF examination
In 62 (93%) patients a lumbar puncture was performed, but
only in 57 (85%) patients the results on both cell count and
protein level were available. The interval between onset of
weakness and lumbar puncture was median 4 days (IQR
2–8 days, range 0–26 days). A mild pleocytosis was
observed in 27 children (47%); the cell count ranged
between 5 and 10 leukocytes/ll in 15 children, 11 and 20
leukocytes/ll in 10 children and 21 and 50 leukocytes/ll in
3 children. Two children showed an increased cell count
with 54 and 60 leukocytes/ll, but both children may have
had a traumatic puncture; no other diagnosis was made.
CSF protein level was increased in 46 (77%) of the patients
(Fig. 1a). Of the children with a raised CSF protein level,
at least four had a traumatic puncture. Most CSF samples
obtained more than 1 week after onset of weakness showed
an increased protein level.
Nerve conduction studies
In 53 (79%) patients data from NCS were available for the
current study (Fig. 1b). The median number of days between
onset of weakness and NCS was 9 days (IQR 5–14 days,
range 1–37 days). In 48 (91%) children, the NCS showed
evidence for the presence of a poly(radiculo)neuropathy and
supported the diagnosis GBS. In the remaining five (9%)
children, the NCS were normal and not repeated. AIDP was
the predominant subtype present in 53 children (60%), fol-
lowed by AMAN in 2 children (4%), both AMSAN and
unresponsive nerves in one child (2%) In 12 children (23%),
the abnormal NCS were equivocal and could not be further
classified. Of the 7 children with persistent paraparesis, NCS
of the arms was performed in 2 children, and in both patients
the results indicated a demyelinating polyneuropathy of both
arms and legs. The electrophysiological subtype was not
related to the interval between onset of weakness and per-
forming the NCS.
Brighton classification
The classification according to the Brighton criteria depends
on the completeness of the data regarding the key diagnostic
characteristics. Therefore, the criteria were validated sepa-
rately for the subgroup of patients with a complete dataset and
for the total group of patients (Online Resource Table 2). In
the 46 children with a complete dataset, 33 children reached
level 1, 11 children reached level 2, one child reached level 3
and one child reached level 4. From the children who did not
reach level 1, 8 children (17%) either had a normal CSF
protein level or normal NCS, 3 children (7%) had both a
normal CSF protein level and a normal NCS. The child who
reached level 3 had more than 50 leukocytes in CSF. The
patient who only reached level 4 did not have a monophasic
disease course. The sensitivity was 72% (95% CI 57–84) for
level 1, 96% (95% CI 85–99) for level 2 and 98% (95% CI
88–100) for level 3. Patients with various Brighton levels did
not differ regarding age, sex, preceding event, disease
severity and outcome. As expected, the Brighton criteria had
a lower sensitivity in the whole group of patients because of
missing data (Online Resource Table 2).
Discussion
In the current study, we described in detail the variation in
key clinical characteristics in 67 children with GBS. The
far majority showed a rapidly progressive flaccid
A B
Fig. 1 Diagnostic test results. a Frequency of increased protein levels
in CSF in children with GBS. Reference values CSF protein in
children used in Sophia children’s hospital: 1–3 months: 0.24–0.65 g/
L, 3–6 months: 0.23–0.37 g/L, 6–12 months: 0.17–0.35 g/L,
1–10 years: 0.16–0.31 g/L, 10–18 years: 0.24–0.49 g/L. %, the
percent of patients with an increased CSF protein level. b Results
nerve conduction studies in children with GBS
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tetraparesis with reduced reflexes reaching nadir within
4 weeks, followed by slow recovery without relapses. The
diagnosis was confirmed in most cases by the presence of
an increased protein level in CSF and findings compatible
with a poly(radiculo)neuropathy in NCS. In a minority of
children, the presentation differed from this prototypic
form. First, 13 (23%) children presented with paraparesis
of the legs and seven (11%) showed a persistent para-
paresis during the entire course of disease. In none of these
patients, there was evidence for myelum involvement
based on clinical examination, MRI of the spine (conducted
in 2 of 7 cases), or clinical re-examination during follow-
up. A similar paraplegic variant of GBS has been reported
previously in adult patients (18). Second, CSF protein level
was normal in 14 (23%) children, and a CSF pleocytosis
between 5 and 50 leukocytes/ll was observed in 28 (49%)
children. Third, results of NCS were equivocal in 12 (23%)
and normal in 5 (9%) children, implying that in one-third
the electrophysiological subtype could not be defined in a
single NCS using current criteria. Additional diagnostic
work-up and a follow-up of at least 6 months in these
atypical cases revealed no alternative diagnosis, indicating
that these variations are part of the spectrum of phenotypes
within the diagnosis of GBS. Children with a complete
dataset reached Brighton level 1 in 72%, and at least level 3
in 98%, indicating that the Brighton criteria have a high
sensitivity for the diagnosis of GBS in children. These
results show that children usually present with the classic
symptoms of GBS and fulfill the current diagnostic criteria.
Accuracy of the Brighton criteria developed for vaccine
safety monitoring is especially relevant for children who are
frequently exposed to vaccinations. Two previous studies
have reported on the sensitivity of the Brighton criteria for
GBS in children [4, 12]. A study from India was based on the
national polio surveillance program in children (\15 years)
and selected 79 (11%) patients with a full diagnostic workup
from an original population of 718 children diagnosed with
GBS [12]. This study showed a comparably high frequency of
patients reaching level 1 (62%) or at least level 3 (86%), and a
similar frequency of patients with normal CSF results (16%)
and equivocal NCS (29%). The authors indicated that the
investigated population in their study was likely biased
towards more severe cases who more frequently get a full
diagnostic work-up. In a study from South-Korea, none of 18
children reached level 1, but all reached level 2 or 3 [4].
Compared to a previous study in adult patients from The
Netherlands, the Brighton criteria are more sensitive for the
diagnosis of pediatric GBS [5]. Only 61% of adult patients
reached level 1, compared to 72% of children in the current
study. This difference is almost fully explained by the lower
frequency of an increased protein level in CSF in adults
compared to children, despite the fact that the timing of the
lumbar puncture in adults and children was similar. A
limitation of all studies investigating the performance of the
Brighton criteria in pediatric GBS, including ours, was the
retrospective design and the influence of missing data.
Additional investigations of CSF and NCS were not
performed in ten children (15%). Most frequently, these
studies were not conducted because the patient had a mild
form of GBS or no alternative diagnosis was suspected.
Physicians may also be more reluctant to perform invasive
or painful investigations in children than adults. Less-in-
vasive techniques than lumbar puncture and NCS may be
considered to confirm the diagnosis of GBS. Recently,
gadolinium-enhanced magnetic resonance imaging of the
nerve roots was reported to be equally accurate as NCS
[13], and lumbar puncture [14]. MRI may be especially
valuable in centers with limited pediatric neurophysiolog-
ical expertise. Other diagnostic techniques potentially
useful in children are the compound muscle action poten-
tial scan (CMAP scan) [15] and nerve ultrasound [16]. To
further improve the diagnostic criteria for GBS, the
specificity needs to be defined in children with similar
clinical presentations as GBS but an alternative diagnosis.
In addition, prospective studies are required including
patients with the full spectrum of subforms of GBS. The
Brighton criteria were developed primarily for surveillance
and vaccine safety studies rather than for clinical decision-
making in the diagnostic work-up in clinical practice in
individual patients. Development of protocols for routine
diagnostic work-up and criteria for early diagnosis would
support the early diagnosis of GBS in children.
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